
October 19, 2023
Pure Life Healthcare Management aims to change the healthcare landscape for people suffering from post-traumatic stress disorder (PTSD) with more than 20 services to support PTSD and trauma, creating a wrap-around healthcare ecosystem that provides patients with everything they need to heal.
The company is backed by an experienced team with a deep understanding of issues surrounding mental health. It is also structured to leverage its own value chain, which includes wrap-around care clinics, occupational therapy, alternative medical treatments, pharmacies and partnerships with organizations such as Heroes Haven Society.
Key Services and PartnershipsPure Life Healthcare Management’s wraparound approach to healthcare will provide support throughout the entire healing process, from counseling and medical testing to dentistry and physiotherapy. The majority of clients are expected to require only a light to medium touch, with one to six visits per month. However, Pure Life also expects a minority of highly complex cases which will require up to $100,000 annually per client with 10 to 20 visits per month.
Company Highlights
- Over 1.3 million Canadians currently struggle with PTSD and trauma, a population largely underserved by the country's mental health services.
- Canada is implementing a National Strategy for PTSD focused on prevention, early treatment and intervention, increasing funding for mental health services and looking for partners.
- Pure Life Healthcare Management is strategically positioned to be among these partners.
- Pure Life Healthcare Management offers more than 20 services to support PTSD and trauma, creating a wrap-around healthcare ecosystem that provides patients with everything they need to heal.
- The company is backed by an experienced leadership team and a business structure designed to maximize the value chain, which includes:
- Wrap-around care clinics
- Pharmacies
- Alternative medicines
- Occupational therapies
- Partnerships
- Joint ventures
- Real estate and commercial holdings
- One of Pure Life Healthcare Management's most prominent partnerships is with the non-profit Heroes Haven Society, which provides free testing and support for individuals suffering from trauma.
- The majority of Pure Life Healthcare Management’s revenue will stem from government and insurance benefits.
- Pure Life Healthcare Management has begun with a virtual model, and is preparing to acquire its first physical location in 2023. The virtual presence will be maintained to serve the remote and restricted community, and as a way to measure patient concentration by area, driving physical location demand and profitability from day one. This strategy is expected to deliver the following revenues:
- Phase 1 (2023): $690,000 with 14,400 clients and one physical location.
- Phase 2 (2024): $29.90 million with 27,000 clients and two physical locations.
- Phase 3 (2025): $90.85 million with 40,000 clients and four physical locations.
This Pure Life Healthcare Management profile is part of a paid investor education campaign.*
Click here to connect with Pure Life Healthcare Management to receive an Investor Presentation

Sign up to get your FREE
Standard Uranium Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
The Conversation (0)
26 March
Standard Uranium: Fuel the Future!
A Canadian junior uranium exploration and project generator company with a district-scale Athabasca Basin portfolio.
A Canadian junior uranium exploration and project generator company with a district-scale Athabasca Basin portfolio. Keep Reading...
3h
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications... Keep Reading...
23 March
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...
10 March
SVN-114 selected as the lead candidate for PTSD discovery programme
Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
09 March
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
06 March
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
05 March
Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute
Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Latest News

Sign up to get your FREE
Standard Uranium Investor Kit
and hear about exciting investment opportunities.
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00



